Several key findings support this observation: (1) a notable reduction in tumor volume in the 14-day CBD pretreatment group compared to the placebo and 3-day CBD groups; (2) a decrease in the expression of SOX2, a marker of stem-like properties, along with immune checkpoint regulators IDO and PD-L1 in the 14-day CBD pretreatment group; (3) a reduction in MGMT and Ki-67, which are biomarkers associated with DNA repair and cellular proliferation, respectively. The gene discussed is IDO1; the disease is neoplasm.